| . | Entire cohort (n = 50) . | ASD closure alone (n = 20) . | Upfront CA (n = 30) . | ASD closure alone vs. upfront CA (P value) . |
|---|---|---|---|---|
| Follow-up after ASD closure (months) | 49 ± 23 | 50 ± 24 | 49 ± 22 | 0.782 |
| Recurrence of AF | 18 (36) | 12 (60) | 6 (20) | 0.006 |
| Time to AF recurrence after ASD closure (months) | 23 (1–47) | 16 (1–47) | 38 (12–102) | 0.068 |
| Antiarrhythmic drug usage | 19 (38) | 14 (70) | 5 (17) | <0.001 |
| Class I/II/III/IV/digoxin | 6/7/0/3/3 | 6/2/0/3/3 | 0/5/0/0/0 |
| . | Entire cohort (n = 50) . | ASD closure alone (n = 20) . | Upfront CA (n = 30) . | ASD closure alone vs. upfront CA (P value) . |
|---|---|---|---|---|
| Follow-up after ASD closure (months) | 49 ± 23 | 50 ± 24 | 49 ± 22 | 0.782 |
| Recurrence of AF | 18 (36) | 12 (60) | 6 (20) | 0.006 |
| Time to AF recurrence after ASD closure (months) | 23 (1–47) | 16 (1–47) | 38 (12–102) | 0.068 |
| Antiarrhythmic drug usage | 19 (38) | 14 (70) | 5 (17) | <0.001 |
| Class I/II/III/IV/digoxin | 6/7/0/3/3 | 6/2/0/3/3 | 0/5/0/0/0 |
Values are expressed as n (%), mean ± SD, or median (range).
AF, atrial fibrillation; ASD, atrial septal defect; CA, catheter ablation; SD, standard deviation.
| . | Entire cohort (n = 50) . | ASD closure alone (n = 20) . | Upfront CA (n = 30) . | ASD closure alone vs. upfront CA (P value) . |
|---|---|---|---|---|
| Follow-up after ASD closure (months) | 49 ± 23 | 50 ± 24 | 49 ± 22 | 0.782 |
| Recurrence of AF | 18 (36) | 12 (60) | 6 (20) | 0.006 |
| Time to AF recurrence after ASD closure (months) | 23 (1–47) | 16 (1–47) | 38 (12–102) | 0.068 |
| Antiarrhythmic drug usage | 19 (38) | 14 (70) | 5 (17) | <0.001 |
| Class I/II/III/IV/digoxin | 6/7/0/3/3 | 6/2/0/3/3 | 0/5/0/0/0 |
| . | Entire cohort (n = 50) . | ASD closure alone (n = 20) . | Upfront CA (n = 30) . | ASD closure alone vs. upfront CA (P value) . |
|---|---|---|---|---|
| Follow-up after ASD closure (months) | 49 ± 23 | 50 ± 24 | 49 ± 22 | 0.782 |
| Recurrence of AF | 18 (36) | 12 (60) | 6 (20) | 0.006 |
| Time to AF recurrence after ASD closure (months) | 23 (1–47) | 16 (1–47) | 38 (12–102) | 0.068 |
| Antiarrhythmic drug usage | 19 (38) | 14 (70) | 5 (17) | <0.001 |
| Class I/II/III/IV/digoxin | 6/7/0/3/3 | 6/2/0/3/3 | 0/5/0/0/0 |
Values are expressed as n (%), mean ± SD, or median (range).
AF, atrial fibrillation; ASD, atrial septal defect; CA, catheter ablation; SD, standard deviation.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
